Market Research Report : Anti diabetic pharmaceuticals market in india 2015 - Sample

Insert Cover Image using Slide Master View

Do not distort

Anti-Diabetic Pharmaceuticals Market – India

July 2015

2 ANTI-DIABETIC PHARMACEUTICALS MARKET IN INDIA 2015

Drivers: Increase in the number of diabetic

patients

Introduction of newer and better drugs

Increasing aging population

Comprehensive health insurances policies covering diabetes

Drug Regulation and

Patents

Anti-diabetic pharmaceuticals market in India is valued at INR x bn in 2014

Market is expected to grow at a CAGR of x% from 2013 to 2018

Anti-diabetes therapeutic segment is the second fastest growing segment, after oncology

Challenges: Price regulation in insulin market

Use of complementary and alternative medicines

Maintenance of healthy lifestyle to avoid diabetes

Phases of clinical trial

Approval and licensing of drugs

Patents

Drivers & Challenges

Market

Executive Summary

Competition

Major Players

Company A Company C Company E

Company B Company D Company F

3

•Macroeconomic Indicators

•Introduction

•Market Overview

•Drivers & Challenges

•Government Initiatives

•Market Value Chain

•Regulation and Patents

•Competitive Landscape

•Strategic Recommendation

•Appendix

ANTI-DIABETIC PHARMACEUTICALS MARKET IN INDIA 2015

4

SAMPLE Macroeconomic Indicators (x/x)

Lending Rate: Annual

k l j i h g f e a d c b %

Per Annum

y1 2011-12

x2

y2

2014-15 y4

x4

2013-14 y3

x3

2012-13

x1

Max Min

Trade Balance: Annual

Commercial Bank Rates: Key Lending Rates as Prescribed by RBI (All Commercial Banks including SBI) - Minimum Rate General

N.B.: 2012-13 encompasses figure for Apr – Nov 2012

FDI: Annual

d

d

b

a

INR

tn

x3

2011-12

x1

2010-11

x2

2013-14

x4

2012-13

a

b

c

d

2010-11

y3

2011-12

y2

2012-13 2009-10

INR bn

y1 y4


5

SAMPLE The total diabetes market can be broadly classified into two parts

Oral anti-diabetic drug segment presents a huge opportunity for market players

Y X

Diabetes Market

YY XX

• Anti-diabetic pharmaceuticals occupy around x-y% of the market share, with oral drugs constituting around a-

b% of the market share

• Pharmaceutical sector is expected to be the largest source of product revenue over the next ten years

• Medical devices segment is composed of instruments for diagnosis and monitoring of the disease, and a range

of devices for administering insulin


6

SAMPLE The anti-diabetes pharmaceuticals consists of mainly six classes of drugs

Generic name

a1

How they work Trade name

Anti-diabetic medications treat Diabetes Mellitus by lowering glucose levels in the blood

A a2 a3

B b1 b2 b3

C c1 c2

d1

c3

D d2 d3

E e3 e1 e2

F f3 f1 f2


7

SAMPLE Increasing prevalence of diabetes is ensuring rapid growth for the global diabetes market

• XX

• XX

• XX

• XX

Global Market – Overview Market Size and Growth

Market Segmentation

a

c

d

b

0

x5 A

x3

INR tn

2014

x2

2018e

x6

2017e 2016e

x4

2015e 2013

x1

x

y

x

y

x y 2013 2015e

0

C

A

B

AFR

x6 x7

mn

SACA NAC

x5 x4

MENA

x3

EUR SEA

x2

WP

x1

People Living With Diabetes (2013)

Note: AFR – Africa, SACA – South & Central America, MENA – Middle East & North Africa, NAC – North America & Caribbean, EUR – Europe, SEA – South East Asia, WP – Western Pacific


8

SAMPLE India’s diabetes market is poised to grow over the coming years

Indian Market – Overview Market Size and Growth

Market Segmentation

h g a c b f d e

x7

%

CNS x4 CVS x3

x1

gastro

diabetes

x5 respiratory pain x6

x8 anti-infectives

x2 oncology

Growth in therapeutic segments(2010)

A

B

0

x1

2018e

X

2017e

x6 x5

2016e

INR bn

2013

x4

2015e

x3

2014

x2

x

y

x y

x y 2010 2015e


• XX

• XX

XX

XX

XX

9

SAMPLE The incidence of diabetes is higher in developed countries because of unhealthy lifestyles

North America and Caribbean 2013: x mn 2035e: y mn

Europe 2013: x mn 2035e: y mn

Africa 2013: x mn 2035e: y mn

Western Pacific 2013: x mn 2035e: y mn

Middle East and North America 2013: x mn 2035e: y mn

In 2013, there were ~x mn diabetics in the world, which is expected to increase to ~y mn by 2035

SEA and the Western Pacific Region together account for over x% of all people with undiagnosed diabetes

South East Asia 2013: x mn 2035e: y mn


South and Central America 2013: x mn 2035e: y mn

10

SAMPLE Huge increase in the number of diabetic patients promotes growth of the anti-diabetics pharmaceutical industry

• XX

• XX

Xx

Xx

Xx

• XX

• XX

• XX

Increase in the number of diabetic patients Impact

k r p h d i a g c e q f b m n u o l s j t

a9 Japan Egypt

a10

mn

a6

a3

China

USA

Germany a7

a2

a8 Indonesia

a4

Mexico RF

a1

a5

India

Brazil


Top 10 countries for number of people with diabetes (20-79 years)

Note: RF refers to Russian Federation

It is expected to increase to ~x mn by 2035

11

SAMPLE Price regulation in the insulin market and competition from alternative diabetes treatment hinders growth

• XX

Xx

Xx

Xx

Xx

Xx

xx

Price regulation in insulin market Impact

Competition from complementary and alternative medicines

• XX

Xx

Xx

Xx

Xx

Xx

• XX


12

SAMPLE Various initiatives taken by the government is providing a boost to this market

• XX

• XX • Xx

• Xx

• Xx

• Xx

• Xx

• XX • Xx

• Xx

• Xx

• Xx

• XX

• XX

Indian Council for Diabetic Care

NPCDCS

NRHM


13

SAMPLE Pharmaceutical value chains involve the entire process from drug discovery to drug marketing

X X X X X

A pharmaceutical value chain is a chain of activities which are involved in producing drugs, starting with raw materials and ending with the delivered product

XX XX XX XX XX


14

SAMPLE CDSCO, under the Ministry Of Health and Family Welfare, controls the drug control administration

• XX

• XX

• XX

• XX

• XX

• XX

• XX

• XX

• XX

• XX

Functions undertaken by Central Government Functions undertaken by the State Governments


The licensing and registration of pharmaceuticals in India controlled in a regulated way helps in the proper marketing of the drug continued

15

SAMPLE A

• XX

B • XX

• XX

2014

C • XX

D • XX

2013

E • XX

F • XX

G • XX

H • XX

2012

Some of the drugs approved for marketing in India (x/x)


16

SAMPLE Porter’s Five Forces Analysis

Competitive Rivalry • X Bargaining Power of Suppliers

• X Bargaining Power of Buyers

• X

Threat of Substitutes • X

Threat of New Entrants • X

Impact X

Impact X

Impact X

Impact X

Impact X


Note: CRO refers to contract research organization

17

SAMPLE Public Trading Comparables (FY 20--) – Top 3 Companies

Company A Company B Company C

Market Capitalization (INR mn) X X X

Share Price (INR) X X X

EV/EBITDA (INR mn) X X X

EV/Revenue (INR mn) X X X

PE Ratio X X X

Note: Top 3 Public companies based on the Market Capitalization; Share Price and PE ratio is as of 10/02/2015


Competitive Benchmarking (x/x)

18

SAMPLE

-20

-10

0

10

20

%

Company C

z2

z1

Company B

y2 y1

Company A

x2 x1

Net Margin Operating Margin

Key Ratios of Top 3 Companies – Operational Basis (FY 20--) (x/x)

• XX

• XX

• XX


Competitive Benchmarking (x/x)

19

SAMPLE Public: Domestic Company – Company A (1/4)

Key People

Products and Services

Company Information Offices and Centers – India

Corporate Address XX

Tel No. XX

Fax No. XX

Website XX

Year of Incorporation XX

Ticker Symbol XX

Stock Exchange XX

Name Designation

XX XX

XX XX

XX XX

Mumbai

Head Office

Category Products/Services

Pharmaceutical Products

XX


20

SAMPLE Key Ratios

Financial Summary

• The company earned a net profit of INR 2.7 bn in FY 2013, as compared to net profit of INR 1.8 bn in FY 2012

• The company reported total Income of INR 17.7 bn in FY 2013, registering an increase of 7.05% over FY 2012

• The company earned an operating margin of 17.30% in FY 2013, an increase of 3.21 percentage points over FY 2012

• The company reported a current ratio of 2.18 in FY 2013, an increase of 1.66% over FY 2012

Key Financial Performance Indicators

Net Profit / Loss Total Income

3

2

1

0

20

15

10

5

0

INR bn INR bn

2013

2.7

17.7

2012

1.8

16.5

2011

1.9

14.2

2010

2.3

11.8

Indicators Value (02/10/2015)

Market Capitalization (INR mn) 78,450.5

Total Enterprise Value (INR mn) 75,574.5

EPS (INR) 103.44

PE Ratio (Absolute) 32.96

Particulars y-o-y change

(2013-12) 2013 2012 2011 2010

Profitability Ratios

Operating Margin 3.21 17.30% 14.09% 16.04% 17.00%

Net Margin 4.31 15.02% 10.71% 13.48% 19.51%

Profit Before Tax Margin 4.70 20.56% 15.86% 20.03% 19.78%

Return on Equity 5.02 19.69% 14.67% 17.12% 22.75%

Return on Capital Employed 3.01 21.68% 18.68% 19.86% 19.83%

Return on Working Capital 6.97 59.72% 52.75% 73.42% 24.53%

Return on Assets 2.32 16.57% 14.25% 15.14% 14.28%

Return on Fixed Assets -62.36 36.61% 98.97% 121.08% 114.11%

Cost Ratios

Operating costs (% of Sales) -3.13 82.09% 85.22% 82.52% 82.42%

Administration costs (% of Sales)

-1.53 0.00% 1.53% 1.78% 2.24%

Interest costs (% of Sales) -0.07 0.02% 0.09% 0.03% 0.25%

Liquidity Ratios

Current Ratio 1.66% 2.18 2.14 1.87 3.08

Cash Ratio -45.26% 0.61 1.11 0.66 1.66

Leverage Ratios

Debt to Equity Ratio N.A. N.A. N.A. N.A. N.A.

Debt to Capital Ratio N.A. N.A. N.A. N.A. N.A.

Interest Coverage Ratio 360.14% 764.00 166.04 541.62 69.58

Efficiency Ratios

Fixed Asset Turnover -69.48% 2.04 6.70 6.93 6.49

Asset Turnover -4.07% 0.93 0.96 0.87 0.81

Current Asset Turnover -5.24% 1.80 1.90 1.95 0.94

Working Capital Turnover -6.57% 3.33 3.57 4.20 1.40

Capital Employed Turnover -3.00% 1.27 1.31 1.17 1.13

Improved Decline

Financial Snapshot

Public: Domestic Company – Company A (2/4)


21

SAMPLE Key Business Segments Key Geographic Segments

Business Highlights

Description News

Overview • XX

Diabetes Management • XX

Key Initiatives • XX

25%

82% 83% 75%

17%18%

100%

80%

60%

40%

20%

0%

2013 2012 2011

Outside India India

Public: Domestic Company – Company A (3/4)

80%

100%

60%

40%

20%

0%

2013

100% Pharmaceuticals

XX


22

SAMPLE Public: Domestic Company – Company A – SWOT Analysis (4/4)

• XX • XX

• XX • XX

T O

W S


23

SAMPLE Strategic Recommendations

• XX

Drug Market

• XX

In a highly competitive pharmaceutical industry, effective strategic decisions will help the players to gain a competitive advantage over others

Insulin Market


24

The Anti-Diabetic Pharmaceuticals Market – India report is part of Netscribes’ Healthcare Industry Series. For more detailed information or customized research requirements please contact:

Thank you for the attention

About Netscribes, Inc.

Netscribes, Inc. is a knowledge-consulting and solutions firm with clientele across the globe. The company’s expertise spans areas of investment & business research, business & corporate intelligence, content-management services, and knowledge-software services. At its core lies a true value proposition that draws upon a vast knowledge base. Netscribes, Inc. is a one-stop shop designed to fulfil clients’ profitability and growth objectives.

Phone: +91 22 4098 7600

E-Mail: [email protected]


http://www.netscribes.com/

mailto:[email protected]

Market Research Report : Anti diabetic pharmaceuticals market in india 2015 - Sample

Documents